Posts

Oncolytics Biotech Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

on

Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up

on

CHARM Therapeutics Raises $80M in Oversubscribed Series B for Next-Gen Menin Inhibitor in AML

on

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

on

Oncolytics Biotech Provides Update on Special Meeting of Shareholders

on

Eli Lilly to Acquire Adverum Biotechnologies in Gene Therapy Deal; Captain T Cell Secures €20M Funding

on

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

on

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

on

METiS BioTech Announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial

on

Recent Moves in Biotech Leadership

on

Fortress Biotech and Sentynl Therapeutics Fail to Secure FDA Approval for CUTX-101 in Rare Pediatric Menkes Disease

on

FDA Rejects CUTX-101 for Rare Copper Deficiency Due to Manufacturing Issues

on

IO Biotech Sheds 50% of Staff After FDA Blocks Cancer Vaccine Approval Path

on

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

on

Trinity Biotech Repositions for AI-Driven Growth with CGM+ Biosensor Platform

on

Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

on

GSK Licenses Experimental Shigella Vaccine to Bharat Biotech for Development and Distribution

on

Novo Nordisk CEO Departs Amid Weight-Loss Drug Market Pressures; Flagship Biotech Appoints CEO from Scholar Rock

on

AstraZeneca's China woes recede as focus shifts to upcoming readouts

on

Biotech and Pharma Job Cuts: Opthea and Pfizer Restructure Amid Industry Challenges

on